Organism: Homo sapiens
Gene: Q9Y2F9
Selected probe(set): 202946_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q9Y2F9 (202946_s_at) across 5610 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-5.0969696
Number of Samples:4 / 4

Experimental	OPM-1
	Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code:
Control	MM1.S
	Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code:

Relative Expression (log2-ratio):-3.464179
Number of Samples:3 / 3

Experimental	CAR T cell study 4 (PSCA-28t28Z; post-infusion)
	CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control	CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
	Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

Relative Expression (log2-ratio):-3.4355087
Number of Samples:2 / 2

Experimental	immune cell study 6 (PB; memory)
	Memory B-cells (CD20+/CD10-/CD27+) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27+.
Control	immune cell study 6 (PB; CD21lo)
	Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21lo) isolated from peripheral blood (PB) B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21lo.

Relative Expression (log2-ratio):3.3802233
Number of Samples:75 / 441

Experimental	CML study 1
	Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control	B-CLL study 5
	Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

Relative Expression (log2-ratio):-3.1621075
Number of Samples:2 / 2

Experimental	immune cell study 6 (PB; memory)
	Memory B-cells (CD20+/CD10-/CD27+) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27+.
Control	immune cell study 6 (PB; CD21hi)
	Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21hi) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21hi.

Relative Expression (log2-ratio):-3.1202402
Number of Samples:2 / 2

Experimental	immune cell study 6 (PB; naive)
	Naive B-cells (CD20+/CD10-/CD27-) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27-.
Control	immune cell study 6 (PB; CD21lo)
	Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21lo) isolated from peripheral blood (PB) B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21lo.

Relative Expression (log2-ratio):-2.8704052
Number of Samples:441 / 74

Experimental	B-CLL study 5
	Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control	normal bone marrow sample
	Non-leukemic and healthy bone marrow sample.

Relative Expression (log2-ratio):-2.846839
Number of Samples:2 / 2

Experimental	immune cell study 6 (PB; naive)
	Naive B-cells (CD20+/CD10-/CD27-) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27-.
Control	immune cell study 6 (PB; CD21hi)
	Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21hi) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21hi.

Relative Expression (log2-ratio):2.8271656
Number of Samples:9 / 10

Experimental	ovarian tumor study 17
	Human epithelial tumor cell samples from the ovary of patients with primary clear cell carcinoma. Samples were derived by laser capture microdissection (LCM).
Control	normal ovarian surface epithelial cell sample
	Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases.

Relative Expression (log2-ratio):-2.8000193
Number of Samples:3 / 3

Experimental	oncolytic herpes simplex virus study 2
	Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control	mock infected peripheral nerve sheath tumor (S462) cell sample
	Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.